71 results match your criteria Growth Hormone Replacement in Older Men


ESE audit on management of Adult Growth Hormone Deficiency in clinical practice.

Eur J Endocrinol 2020 Dec 1. Epub 2020 Dec 1.

T Kocjan, Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, Ljubljana, Slovenia.

Guidelines recommend adults with pituitary disease in whom GH therapy is contemplated, to be tested for GH deficiency (AGHD); however, clinical practice is not uniform.

Aims: 1) To record current practice of AGHD management throughout Europe and benchmark it against guidelines; 2) To evaluate educational status of healthcare professionals about AGHD.

Design: On-line survey in endocrine centres throughout Europe. Read More

View Article and Full-Text PDF
December 2020

Effects of hormones and hormone therapy on breast tissue in transgender patients: a concise review.

Endocrine 2020 04 17;68(1):6-15. Epub 2020 Feb 17.

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Purpose: Hormone replacement therapy (HRT) has become a mainstay medical treatment option for management of gender dysphoria in transgender patients of both biologic sexes. Very little is known about the long-term effects of steroid hormone modulation on breast tissue in this population. Most of the data available on the effects of HRT on breast and reproductive tissues come from studies of postmenopausal cisgender women. Read More

View Article and Full-Text PDF

Effects of growth hormone on hepatic insulin sensitivity and glucose effectiveness in healthy older adults.

Endocrine 2019 03 7;63(3):497-506. Epub 2019 Jan 7.

Clinical Endocrine Section, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Purpose: Growth hormone (GH) replacement decreases insulin sensitivity in healthy individuals. However, the effects of GH on organ-specific insulin sensitivity and glucose effectiveness are not well characterized. The purpose of this study was to evaluate the effects of GH administration for 26 weeks on muscle and hepatic insulin sensitivity and glucose effectiveness in healthy older individuals. Read More

View Article and Full-Text PDF

Sex-specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials.

Clin Endocrinol (Oxf) 2019 02 9;90(2):293-300. Epub 2018 Dec 9.

University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Objective: Studies of dehydroepiandrosterone (DHEA) therapy in older adults suggest sex-specific effects on bone mineral density (BMD) and body composition, but the ability of a single study to reach this conclusion was limited. We evaluated the effects of DHEA on sex hormones, BMD, fat mass and fat-free mass in older women and men enrolled in four similar clinical trials.

Design: Pooled analyses of data from four double-blinded, randomized controlled trials. Read More

View Article and Full-Text PDF
February 2019

Trajectories of plasma IGF-1, IGFBP-3, and their ratio in the Mayo Clinic Study of Aging.

Exp Gerontol 2018 06 21;106:67-73. Epub 2018 Feb 21.

Department of Health Sciences Research, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA; Department of Neurology, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA. Electronic address:

Insulin-like growth factor 1 (IGF-1) has been associated with osteoporosis, cardiovascular disease, cancer, neurodegenerative diseases, and mortality in middle and older aged adults. Cross-sectionally, IGF-1 decreases with age and levels of IGF-1 are markedly different between individuals. However, little is known about intra-individual trajectories of IGF-1. Read More

View Article and Full-Text PDF

Hormone Replacement: The Fountain of Youth?

Prim Care 2017 Sep;44(3):481-498

USC Specialty Pharmacy, University of Southern California, School of Pharmacy, 1000 South Fremont Avenue, A-10, Suite 10150, Alhambra, CA 91803, USA.

Natural aging brings reduced production of growth and sex hormones, beginning in middle age, with noticeable physiologic changes by the sixth or seventh decade of life: reduced muscle mass, energy, and exercise capacity and alterations in sexual function. Hormones and hormone precursors have been investigated to delay changes in body composition, strength, and physical and cognitive function. Menopausal hormone therapy is effective for vasomotor and genitourinary symptoms. Read More

View Article and Full-Text PDF
September 2017

Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone.

Metabolism 2017 Apr 19;69:143-147. Epub 2017 Jan 19.

Section on Men's Health, Aging and Metabolism, Brigham and Women's Hospital Harvard Medical School, Boston, MA, United States, 02115. Electronic address:

Growth hormone is the major regulator of growth and body composition. Pulsatile GH secretion declines exponentially with age. Testosterone replacement is being increasingly offered to older men with age-related low testosterone. Read More

View Article and Full-Text PDF

Overweight duration in older adults and cancer risk: a study of cohorts in Europe and the United States.

Eur J Epidemiol 2016 09 14;31(9):893-904. Epub 2016 Jun 14.

Section of Cancer Surveillance, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008, Lyon, France.

Recent studies have shown that cancer risk related to overweight and obesity is mediated by time and might be better approximated by using life years lived with excess weight. In this study we aimed to assess the impact of overweight duration and intensity in older adults on the risk of developing different forms of cancer. Study participants from seven European and one US cohort study with two or more weight assessments during follow-up were included (n = 329,576). Read More

View Article and Full-Text PDF
September 2016

Controversies in testosterone supplementation therapy.

Authors:
Mohit Khera

Asian J Androl 2015 Mar-Apr;17(2):175-6

Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA.

Testosterone has now become one of the most widely used medications throughout the world. The rapid growth of the testosterone market in the past 10 years is due to many factors. We currently have a worldwide aging population. Read More

View Article and Full-Text PDF
December 2015

Clinical Use of Aromatase Inhibitors in Adult Males.

Sex Med Rev 2014 Apr 19;2(2):79-90. Epub 2015 Oct 19.

Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA. Electronic address:

Introduction: There is a growing interest in the treatment of late-onset hypogonadism, another name for the study of testosterone deficiency in an older age group. Initial attempts at testosterone replacement have also brought attention to the possible adverse effects on the patients' cardiovascular risk factors and their prostate health. The "female" hormone estradiol is no longer considered as the feminizing hormone, as it has been identified to have an effect on the sexual and general well-being of adult males. Read More

View Article and Full-Text PDF

Interventions against sarcopenia in older persons.

Curr Pharm Des 2014 ;20(38):5983-6006

Institut du Vieillissement, Universite Toulouse III - Paul Sabatier, 37 Allees Jules Guesde, 31000 Toulouse France.

The term "sarcopenia" describes the age-related loss of skeletal muscle mass and function. It represents a major risk factor for functional loss and disability in older persons. Multiple underlying pathophysiological mechanisms have been posed at the basis of the sarcopenia phenomenon, including intrinsic (e. Read More

View Article and Full-Text PDF

Testosterone Replacement Therapy in Men with Prostate Cancer: What Is the Evidence?

Sex Med Rev 2013 Oct 19;1(3):135-142. Epub 2015 Oct 19.

Department of Urology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.

Introduction: Testosterone is increasingly being recognized as an important hormone in maintaining proper health in aging males. Testosterone replacement therapy in older men with decreased or low-normal testosterone levels has been recognized to improve sexual function, increase lean body mass and decrease fat mass, improve exercise-induced coronary ischemia, and elevate mood, among other benefits. Prostate cancer remains the most common non-skin malignancy in men in the United States, and as hypogonadism is being recognized and treated more, a dilemma has arisen: treating hypogonadism in men previously treated for prostate cancer. Read More

View Article and Full-Text PDF
October 2013

Effects of sex and postmenopausal estrogen use on serum phosphorus levels: a cross-sectional study of the National Health and Nutrition Examination Survey (NHANES) 2003-2006.

Am J Kidney Dis 2014 Feb 17;63(2):198-205. Epub 2013 Sep 17.

Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX; The Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:

Background: Elevation of serum phosphorus concentrations has been associated with cardiovascular events in older women and men. Whether age, sex, or estrogen therapy is associated with different phosphorus levels is unknown.

Study Design: Cross-sectional study. Read More

View Article and Full-Text PDF
February 2014

Cardiometabolic risks during anabolic hormone supplementation in older men.

Obesity (Silver Spring) 2013 May;21(5):968-75

Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA.

Objective: To determine the cardiometabolic risks of testosterone and growth hormone (GH) replacement therapy to youthful levels during aging.

Design And Methods: A double-masked, partially placebo controlled study in 112 men 65-90 years-old was conducted. Transdermal testosterone (5 g vs. Read More

View Article and Full-Text PDF

Is androgen therapy indicated in men with osteoporosis?

Joint Bone Spine 2013 Oct 12;80(5):459-65. Epub 2013 Apr 12.

Service de rhumatologie, CHU d'Angers, 4, rue Larrey, 49933 Angers cedex 9, France; Groupe Etude sur le Remodelage Osseux et les bioMatériaux (GEROM), UPRES EA 4658, IRIS-IBS, Institut de Biologie en Santé, CHU d'Angers, Angers, France. Electronic address:

Male osteoporosis is not rare, and its management is a public health issue. The clinical evaluation must include investigations for one or more etiological factors such as hypogonadism, which is found in 5% to 15% of men with osteoporosis. Gradual development of moderate hypogonadism is the most common situation, and the prevalence of hypogonadism increases with advancing age. Read More

View Article and Full-Text PDF
October 2013

Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - a KIMS database analysis.

Clin Endocrinol (Oxf) 2013 Aug 5;79(2):178-84. Epub 2013 Apr 5.

Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

Objective: Growth hormone (GH) replacement may increase bone mineral density (BMD) in GH-deficient (GHD) adults. The goal of this study was to identify predictors of BMD response to GH replacement in GH naïve adults.

Design And Measurements: This was a retrospective analysis of data extracted from KIMS (Pfizer International Metabolic Database), an international pharmacoepidemiological survey of adult GHD patients from 31 countries. Read More

View Article and Full-Text PDF

Testosterone replacement therapy in reversing "andropause": what is the proof-of-principle?

Rejuvenation Res 2012 Oct 1;15(5):453-65. Epub 2012 Jun 1.

Department of Internal Medicine, Rehabilitation and Geriatrics, Medical School and University Hospitals of Geneva, Geneva, Switzerland.

Abstract Testosterone replacement therapy is often equated with the macho male physique and virility and is viewed by some as an antiaging tonic. The growth in testosterone's reputation and its increased use by men of all ages has seemed to outpace the scientific evidences. This review will aim to examine the uncertainty regarding the nature and the clinical importance of the age-related reduction in the testosterone levels. Read More

View Article and Full-Text PDF
October 2012

Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Endocr Rev 2012 Jun 20;33(3):314-77. Epub 2012 Mar 20.

Improving physical function and mobility in a continuously expanding elderly population emerges as a high priority of medicine today. Muscle mass, strength/power, and maximal exercise capacity are major determinants of physical function, and all decline with aging. This contributes to the incidence of frailty and disability observed in older men. Read More

View Article and Full-Text PDF

Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study.

Am J Kidney Dis 2011 Nov 19;58(5):737-45. Epub 2011 Aug 19.

Division of Nephrology and Hypertension, Department of Medicine, University of California San Diego, San Diego, CA 92161, USA.

Background: Menopause is associated with urine phosphorus retention, which is mitigated by estrogen therapy. Fibroblast growth factor 23 (FGF-23) is a hormone originating from bone that regulates urine phosphorus excretion. Whether sex or estrogen therapy is associated with different FGF-23 levels is unknown. Read More

View Article and Full-Text PDF
November 2011

AKT1 G205T genotype influences obesity-related metabolic phenotypes and their responses to aerobic exercise training in older Caucasians.

Exp Physiol 2011 Mar 19;96(3):338-47. Epub 2010 Nov 19.

Department of Exercise Science and Physical Education, McDaniel College, 2 College Hill, Westminster, MD 21157, USA.

As part of the insulin signalling pathway, Akt influences growth and metabolism. The AKT1 gene G205T (rs1130214) polymorphism has potential functional effects. Thus, we determined whether the G205T polymorphism influences metabolic variables and their responses to aerobic exercise training. Read More

View Article and Full-Text PDF

Effects of testosterone administration on nocturnal cortisol secretion in healthy older men.

J Gerontol A Biol Sci Med Sci 2010 Nov 30;65(11):1185-92. Epub 2010 Jul 30.

Diabetes Unit, Laboratory of Clinical Investigation, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, Maryland, USA.

In animal studies, testosterone decreases, whereas estrogen increases, cortisol production. In one clinical study, short-term testosterone replacement attenuated corticotrophin-releasing hormone-stimulated cortisol secretion during leuprolide-induced hypogonadism in young men. The effects of longer term testosterone treatment on spontaneous cortisol secretion in younger or older men are unknown. Read More

View Article and Full-Text PDF
November 2010

Sarcopenia.

Authors:
David R Thomas

Clin Geriatr Med 2010 May;26(2):331-46

Division of Geriatric Medicine, Saint Louis University Medical Center, Saint Louis University School of Medicine, 1402 South Grand Boulevard, M28, St Louis, MO 63104, USA.

The definition of sarcopenia continues to evolve, from an observational phenomenon to a differential diagnostic approach. Clinical relevance for sarcopenia is defined by a loss in lean muscle mass and impairment of functional status. A therapeutic approach to the loss of skeletal muscle mass and strength in older persons depends on correct classification. Read More

View Article and Full-Text PDF

Cardiovascular aspects of menopausal hormone replacement therapy.

Climacteric 2009 ;12 Suppl 1:41-6

Department of Medical Sciences, Center for Clinical & Basic Research, IRCCS San Raffaele, Rome, Italy.

Cardiovascular disease is the leading cause of death in postmenopausal women in Western countries. Despite preventive strategies, in the past decades, the incidence of cardiovascular events has shown a decline in men but a rise in women, matching the growth of the population of postmenopausal women. Several epidemiological findings suggest the causative role of ovarian hormone deficiency in the development of cardiovascular disease in women. Read More

View Article and Full-Text PDF
January 2010

Effect of hormone replacement therapy on inflammatory biomarkers.

Adv Clin Chem 2009 ;47:59-93

2nd Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece.

Cardiovascular disease is the leading cause of death among women. Inflammation plays a central role in the pathogenesis of many forms of vascular disease, including atherosclerosis. Women present with cardiovascular disease a decade after men and this has been attributed to the protective effect of female ovarian sex hormones. Read More

View Article and Full-Text PDF

Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men.

J Clin Endocrinol Metab 2009 Oct 14;94(10):3833-41. Epub 2009 Jul 14.

Endocrine Section, Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224, USA.

Context: With aging, GH, IGF-I, and sex steroid concentrations and glucose tolerance decrease, and body fat and serum lipids increase.

Objective: The aim of the study was to assess GH and/or sex steroid administration effects on serum glucose, insulin, insulin sensitivity, and lipids in older individuals.

Design: A double-masked, 2 x 2 factorial, placebo-controlled, double-dummy design was used for the study. Read More

View Article and Full-Text PDF
October 2009

Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp.

J Clin Endocrinol Metab 2009 Jul 7;94(7):2544-50. Epub 2009 Apr 7.

Department of Medicine, Endocrine Research Unit, Mayo School of Graduate Medical Education, Clinical Translational Science Center, Mayo Clinic, Rochester, Minnesota 55905, USA.

Background: Sex steroids are prominent regulators of pulsatile GH secretion.

Hypothesis: An experimentally controlled sex-steroid milieu will permit detection of nonsteroidal factors that determine GH secretion.

Subjects: Eleven young (age, 24 +/- 0. Read More

View Article and Full-Text PDF

Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone.

Am J Clin Nutr 2009 May 25;89(5):1459-67. Epub 2009 Mar 25.

Division of Geriatrics and Nutritional Sciences, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA.

Background: Age-related reductions in serum dehydroepiandrosterone (DHEA) concentrations may be involved in bone mineral density (BMD) losses.

Objective: The objective was to determine whether DHEA supplementation in older adults improves BMD when co-administered with vitamin D and calcium.

Design: In year 1, a randomized trial was conducted in which men (n = 55) and women (n = 58) aged 65-75 y took 50 mg/d oral DHEA supplements or placebo. Read More

View Article and Full-Text PDF

Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.

J Cardiovasc Med (Hagerstown) 2009 Jan;10(1):85-92

Centre for Clinical and Basic Research, IRCCS San Raffaele Roma, Via della Pisana 234, 00163 Rome, Italy.

Cardiovascular disease is the leading cause of death in women in Western countries. Despite preventive strategies, in the past decades the incidence of cardiovascular events has shown a decline in men but a rise in women, matching the growth of the population of postmenopausal women. Several epidemiological findings suggest the causative pathophysiological role of ovarian hormone deficiency in the development of cardiovascular disease in women. Read More

View Article and Full-Text PDF
January 2009

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

Ann Intern Med 2008 Nov;149(9):601-11

University of Virginia, Charlottesville, Virginia 22908, USA.

Background: Growth hormone secretion and muscle mass decline from midpuberty throughout life, culminating in sarcopenia, frailty, decreased function, and loss of independence. The decline of growth hormone in the development of sarcopenia is one of many factors, and its etiologic role needs to be demonstrated.

Objective: To determine whether MK-677, an oral ghrelin mimetic, increases growth hormone secretion into the young-adult range without serious adverse effects, prevents the decline of fat-free mass, and decreases abdominal visceral fat in healthy older adults. Read More

View Article and Full-Text PDF
November 2008

Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease.

Curr Cardiol Rev 2008 Nov;4(4):309-22

Division of Vascular Surgery, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA.

Cardiovascular disease (CVD) is more common in men and postmenopausal women than premenopausal women, suggesting vascular benefits of female sex hormones. Experimental data have shown beneficial vascular effects of estrogen including stimulation of endothelium-dependent nitric oxide, prostacyclin and hyperpolarizing factor-mediated vascular relaxation. However, the experimental evidence did not translate into vascular benefits of hormone replacement therapy (HRT) in postmenopausal women, and HERS, HERS-II and WHI clinical trials demonstrated adverse cardiovascular events with HRT. Read More

View Article and Full-Text PDF
November 2008